Characterization of the global stabilizing substitution A77V and its role in the evolution of CTX-M β-Lactamases

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 6741-6748

  Patel, Meha P ^a   Fryszczyn, Bartlomiej G ^a   Palzkill, Timothy ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAMASE CTX M; CEFALOTIN; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN; NITROCEFIN; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG HYDROLYSIS; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME STABILITY; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; STEADY STATE; SUBSTITUTION REACTION; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; ESCHERICHIA COLI; GENETICS; METABOLISM; MOLECULAR EVOLUTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEFTAZIDIME; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; EVOLUTION, MOLECULAR; MUTATION;

EID: 84946207770     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00618-15     Document Type: Article

References (46)

1. Bush K. 2013. Proliferation and significance of clinically relevant β-lactamases. Ann N Y Acad Sci 1277:84-90. http://dx.doi.org/10.1111/nyas.12023.
2. Fromer M, Shifman JM. 2009. Tradeoff between stability and multispecificity in the design of promiscuous proteins. PLoS Comput Biol 5:e1000627. http://dx.doi.org/10.1371/journal.pcbi.1000627.
3. Tokuriki N, Tawfik DS. 2009. Stability effects of mutations and protein evolvability. Curr Opin Struct Biol 19:596-604. http://dx.doi.org/10.1016/j.sbi.2009.08.003.
4. Brown NG, Pennington JM, Huang W, Ayvaz T, Palzkill T. 2010. Multiple global suppressors of protein stability defects facilitate the evolution of extended-spectrum TEM β-lactamases. J Mol Biol 404:832-846. http://dx.doi.org/10.1016/jjmb.2010.10.008.
5. Wang X, Minasov G, Shoichet BK. 2002. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J Mol Biol 320:85-95. http://dx.doi.org/10.1016/S0022-2836(02)00400-X.
6. Orencia MC, Yoon JS, Ness JE, Stemmer WPC, Stevens RC. 2001. Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. Nat Struct Biol 8:238-242. http://dx.doi.org/10.1038/84981.
7. Bloom JD, Labthavikul ST, Otey CR, Arnold FH. 2006. Protein stability promotes evolvability. Proc Natl Acad Sci USA 103:5869-5874. http://dx.doi.org/10.1073/pnas.0510098103.
8. Huang W, Palzkill T. 1997. A natural polymorphism in beta-lactamase is a global suppressor. Proc Natl Acad Sci USA 94:8801-8806. http://dx.doi.org/10.1073/pnas.94.16.8801.
9. Marciano DC, Pennington JM, Wang X, Wang J, Chen Y, Thomas VL, Shoichet BK, Palzkill T. 2008. Genetic and structural characterization of an L201P global suppressor substitution in TEM-1 beta-lactamase. J Mol Biol 384:151-164. http://dx.doi.org/10.1016/j.jmb.2008.09.009.
10. Tzouvelekis LS, Bonomo RA. 1999. SHV-type beta-lactamases. Curr Pharm Des 5:847-864.
11. Knox JR. 1995. Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob Agents Chemother 39:2593-2601. http://dx.doi.org/10.1128/AAC.39.12.2593.
12. Thomas VL, McReynolds AC, Shoichet BK. 2010. Structural bases for stability-function tradeoffs in antibiotic resistance. J Mol Biol 396:47-59. http://dx.doi.org/10.1016/jjmb.2009.11.005.
13. Shoichet BK, Baase WA, Kuroki R, Matthews BW. 1995. A relationship between protein stability and protein function. Proc Natl Acad Sci USA 92:452-456. http://dx.doi.org/10.1073/pnas.92.2.452.
14. Thomas VL, Golemi-Kotra D, Kim C, Vakulenko SB, Mobashery S, Shoichet BK. 2005. Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM beta-lactamase. Biochemistry 44:9330-9338. http://dx.doi.org/10.1021/bi0502700.
15. Sideraki V, Huang W, Palzkill T, Gilbert HF. 2001. A secondary drug resistance mutation of TEM-1 beta-lactamase that suppresses misfolding and aggregation. Proc Natl Acad Sci USA 98:283-288. http://dx.doi.org/10.1073/pnas.98.1.283.
16. D'Andrea MM, Arena F, Pallecchi L, Rossolini GM. 2013. CTX-M-type β-lactamases: a successful story of antibiotic resistance. Int J Med Microbiol 303:305-317. http://dx.doi.org/10.1016/j.ijmm.2013.02.008.
17. Cantón R, González-Alba JM, Galán JC. 2012. CTX-M enzymes: origin and diffusion. Front Microbiol 3:110. http://dx.doi.org/10.3389/fmicb.2012.00.
18. Rossolini GM, D'Andrea MM, Mugnaioli C. 2008. The spread of CTX-M-type extended-spectrum beta-lactamases. Clin Microbiol Infect 14(Suppl 1):33-41. http://dx.doi.org/10.1111/j.1469-0691.2007.01867.x.
19. Bae IK, Lee BH, Hwang HY, Jeong SH, Hong SG, Chang CL, Kwak H-S, Kim HJ, Youn H. 2006. A novel ceftazidime-hydrolysing extended-spectrum beta-lactamase, CTX-M-54, with a single amino acid substitution at position 167 in the omega loop. J Antimicrob Chemother 58:315-319. http://dx.doi.org/10.1093/jac/dkl252.
20. Bonnet R. 2004. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 48:1-14. http://dx.doi.org/10.1128/AAC48.1.1-14.2004.
21. Novais A, Cantón R, Coque TM, Moya A, Baquero F, Galán JC. 2008. Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance. Antimicrob Agents Chemother 52:2377-2382. http://dx.doi.org/10.1128/AAC.01658-07.
22. Kimura S, Ishii Y, Tateda K, Yamaguchi K. 2007. Predictive analysis of ceftazidime hydrolysis in CTX-M-type β-lactamase family members with a mutational substitution at position 167. Int J Antimicrob Agents 29: 326-331. http://dx.doi.org/10.1016/j.ijantimicag.2006.09.014.
23. Kimura S, Ishiguro M, Ishii Y, Alba J. 2004. Role of a mutation at position 167 of CTX-M-19 in ceftazidime hydrolysis. Antimicrob Agents Chemother 48:1454-1460. http://dx.doi.org/10.1128/AAC.48.5.1454-1460.2004.
24. Bonnet R, Recule C, Baraduc R, Chanal C, Sirot D, De Champs C, Sirot J. 2003. Effect of D240G substitution in a novel ESBL CTX-M-27. J Antimicrob Chemother 52:29-35. http://dx.doi.org/10.1093/jac/dkg256.
25. Chen Y, Delmas J, Sirot J, Shoichet B, Bonnet R. 2005. Atomic resolution structures of CTX-M beta-lactamases: extended spectrum activities from increased mobility and decreased stability. J Mol Biol 348:349-362. http://dx.doi.org/10.1016/jjmb.2005.02.010.
26. Delmas J, Chen Y, Prati F, Robin F, Shoichet BK, Bonnet R. 2008. Structure and dynamics of CTX-M enzymes reveal insights into substrate accommodation by extended-spectrum beta-lactamases. J Mol Biol 375: 192-201. http://dx.doi.org/10.1016/jjmb.2007.10.026.
27. Poirel L, Naas T, Thomas ILE, Karim A, Bingen E, Nordmann P, Debre R. 2001. CTX-M-type extended-spectrum β-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. Antimicrob Agents Chemother 45:3355-3361. http://dx.doi.org/10.1128/AAC.45.12.3355-3361.2001.
28. Delmas J, Robin F, Carvalho F, Mongaret C, Bonnet R. 2006. Prediction of the evolution of ceftazidime resistance in extended-spectrum β-lactamase CTX-M-9. Antimicrob Agents Chemother 50:731-738. http://dx.doi.org/10.1128/AAC.50.2.731-738.2006.
29. Adamski CJ, Cardenas AM, Brown NG, Horton LB, Sankaran B, Prasad BVV, Gilbert HF, Palzkill T. 2015. Molecular basis for the catalytic specificity of the CTX-M extended-spectrum β-lactamases. Biochemistry 54:447-457. http://dx.doi.org/10.1021/bi501195g.
30. Petrosino J, Rudgers G, Gilbert H, Palzkill T. 1999. Contributions of aspartate 49 and phenylalanine 142 residues of a tight binding inhibitory protein of β-lactamases. J Biol Chem 274:2394-2400. http://dx.doi.org/10.1074/jbc.274.4.2394.
31. Amann E, Brosius J, Ptashne M. 1983. Vectors bearing a hybrid trp-lac promoter useful for regulated expression of cloned genes in Escherichia coli. Gene 25:167-178. http://dx.doi.org/10.1016/0378-1119(83)90222-6.
32. Studier FW, Moffatt BA. 1986. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol 189: 113-130. http://dx.doi.org/10.1016/0022-2836(86)90385-2.
33. Majiduddin FK, Palzkill T. 2003. An analysis of why highly similar enzymes evolve differently. Genetics 466:457-466.
34. Lenski RE, Simpson SC, Nguyen TT. 1994. Genetic analysis of a plasmid-encoded, host genotype-specific enhancement of bacterial fitness. J Bacteriol 176:3140-3147.
35. Ishii Y, Galleni M, Ma L, Frère J-M, Yamaguchi K. 2007. Biochemical characterisation of the CTX-M-14 beta-lactamase. Int J Antimicrob Agents 29:159-164. http://dx.doi.org/10.1016/j.ijantimicag.2006.09.005.
36. Brown NG, Palzkill T. 2010. Identification and characterization of beta-lactamase inhibitor protein-II (BLIP-II) interactions with beta-lactamases using phage display. Protein Eng Des Sel 23:469-478. http://dx.doi.org/10.1093/protein/gzq017.
37. Deng Z, Huang W, Bakkalbasi E, Brown NG, Adamski CJ, Rice K, Muzny D. 2012. Deep sequencing of systematic combinatorial libraries reveals β-lactamase sequence constraints at high resolution. J Mol Biol 424:150-167. http://dx.doi.org/10.1016/jjmb.2012.09.014.
38. Romero PA, Arnold FH. 2009. Exploring protein fitness landscapes by directed evolution. Nat Rev Mol Cell Biol 10:866-876. http://dx.doi.org/10.1038/nrm2805.
39. Serrano L, Day AG, Fersht AR. 1993. Step-wise mutation of barnase to binase A procedure for engineering increased stability of proteins and an experimental analysis of the evolution of protein stability. J Mol Biol 233: 305-312.
40. Teilum K, Olsen JG, Kragelund BB. 2011. Protein stability, flexibility and function. Biochim Biophys Acta 1814:969-976. http://dx.doi.org/10.1016/j.bbapap.2010.11.005.
41. Celenza G, Luzi C, Aschi M, Segatore B, Setacci D, Pellegrini C, Forcella C, Amicosante G, Perilli M. 2008. Natural D240G Toho-1 mutant conferring resistance to ceftazidime: biochemical characterization of CTX-M-43. J Antimicrob Chemother 62:991-997. http://dx.doi.org/10.1093/jac/dkn339.
42. Shortle D, Lin B. 1985. Genetic analysis of staphylococcal nuclease: identification of three intragenic "global" suppressors of nuclease-minus mutations. Genetics 110:539-555.
43. Blance SJ, Williams NL, Preston ZA, Bishara J, Smyth MS, Maxwell A. 2000. Temperature-sensitive suppressor mutations of the Escherichia coli DNA gyrase B protein. Protein Sci 9:1035-1037. http://dx.doi.org/10.1110/ps.9.5.1035.
44. Fane B, Villafanej R, Mitraki A, King J. 1991. Identification of global suppressors for temperature-sensitive folding mutations of the P22 tail-spike protein. J Biol Chem 261:11640-11648.
45. Weinreich DM, Delaney NF, Depristo MA, Hartl DL. 2006. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312:111-114. http://dx.doi.org/10.1126/science.1123539.
46. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 25:1605-1612. http://dx.doi.org/10.1002/jcc.20084.